Cancer Treatment in Older Adults: What the Latest Research Shows About Age-Related Differences

Table of Contents

• Key Points
• Background: Why This Research Matters
• Study Methods: How the Review Was Conducted
• Characteristics of the Included Studies
• Key Findings: Treatment Differences for All Patients
• Key Findings: Outcomes for Patients Selected for Treatment
• Clinical Implications: What This Means for Patients
• Study Limitations
• Recommendations for Patients and Families
• Frequently Asked Questions
• Source Information

Key Points

• Older adults are less likely to receive cancer treatment and have poorer survival than younger patients, with the largest gaps in those over 80.
• When older patients are carefully selected for treatment, complication rates and survival are often comparable to younger patients.
• Age alone should not determine cancer treatment decisions; a comprehensive geriatric assessment helps predict treatment tolerance.
• Treatment differences were smaller for good-prognosis cancers like breast cancer and larger for poor-prognosis cancers like lung and pancreatic cancer.
• More research is urgently needed, especially on the frailest and oldest patients, to guide evidence-based treatment decisions.

Background: Why This Research Matters

The world's population is aging rapidly. The number of people aged 65 years and older worldwide is projected to more than double in the coming decades, with even faster growth among those over 80 years old. This demographic shift means cancer care for older adults is becoming an increasingly urgent public health priority.

Cancer is fundamentally a disease of aging, yet older patients are often underrepresented in clinical trials and treatment research. Because the older population is extremely diverse—some adults remain fit and active, while others face frailty, chronic illness, or age-related changes in organ function—understanding how age affects cancer treatment is complex.

Several factors are commonly cited when treatment deviates from standard guidelines for older patients. These include the presence of comorbidities (other medical conditions), poorer overall health status, more advanced cancer stage at diagnosis, and patient preferences. This review set out to synthesize the most recent evidence on whether these deviations are justified or whether they represent undertreatment.

Study Methods: How the Review Was Conducted

The research team, led by Esther Bastiaannet (University of Zurich, Switzerland) and Sophie Pilleron (Luxembourg Institute of Health), pre-registered their review protocol in PROSPERO, an international database for systematic reviews (registration number CRD42023450654). They searched two major medical databases—Embase and MEDLINE—for papers published from January 1, 2019, to August 3, 2023.

The search was designed to identify studies that met three inclusion criteria:

1. The paper was primarily focused on treatment differences
2. The comparison was between younger patients and older patients (age 60 and above, with any acceptable age cut-off)
3. The paper was published in English

Studies were excluded if they did not include an age group comparison, focused only on survival outcomes, included only a small subset of patients at a specific cancer stage, or assessed a new surgical technique or non-standard systemic treatment. Conference abstracts, reviews, editorials, and letters were also excluded. Two independent reviewers screened all titles and abstracts, with disputes resolved by a third reviewer.

From this process, 440 papers were selected for full-text review. After applying all criteria, 101 papers were included, plus 1 additional study added by the co-author that had met inclusion criteria but had not appeared in the initial full-text selection—bringing the final total to 102 articles.

Characteristics of the Included Studies

The studies covered a wide range of cancer types. Fifteen studies focused on cancers that occur specifically in females, including breast (4 studies), cervical (4 studies), ovarian (4 studies), endometrial (2 studies), and vulvar (1 study) cancers. A large proportion of studies examined age-related differences in colorectal cancers: 10 studies on rectal cancer, 6 on colon cancer, and 7 on colorectal cancer combined.

Other cancer sites studied included:

• Gastric (stomach) cancer: 5 studies
• Esophageal cancer: 7 studies
• Pancreatic cancer: 12 studies
• Lung cancer: 9 studies (including both small cell lung cancer [SCLC] and non-small cell lung cancer [NSCLC])
• Metastatic disease across various cancer types: 7 studies

Geographically, most research came from Europe, accounting for 36% of studies. The United States contributed 24 studies (23%), and Japan contributed 15 studies (15%). The majority of studies (56%) were conducted at single centers (one hospital or cancer center), while 29 studies (28%) were population-based registry studies, and the remainder were multicenter studies. Study sizes ranged widely, from small cohorts of just over 100 patients to massive registry-based analyses including more than 170,000 patients.

Key Findings: Treatment Differences for All Patients

When all patients were considered together—regardless of whether they actually received treatment—a clear and consistent pattern emerged. Older adults were more likely to receive no treatment at all or no (neo)adjuvant treatment compared to younger adults. This finding held true across cancer types, treatment modalities, countries, and healthcare settings.

Specific Examples of Treatment Gaps

Pancreatic cancer showed some of the largest gaps. In one study, 33% of younger patients received no treatment, compared to 67% of patients over age 60. Lung cancer also showed significant differences in a German study: 4.4% of younger patients received no treatment, compared to 20.2% of patients over 65, and a striking 54.7% of patients over age 80.

For anal cancer, one population-based study found that palliative treatment was actually given more often to older patients: 16.1% of older patients versus 11.2% of younger patients. Similarly, for rectal cancer, bypass surgery or stoma (procedures that manage symptoms rather than cure the cancer) was performed in 5% of patients under 65, 10% of those aged 65–79, and 26% of those aged 80 and older.

Interestingly, one study on cervical cancer found no meaningful difference in chemotherapy rates across age groups: 47.3% for women under 65 versus 47.0% for those 65 and older.

The Age 80 Threshold

Studies that used 80 years as the age cut-off found that differences in treatment were especially pronounced in the oldest patients. For example, differences in chemotherapy non-receipt reached up to 34% when comparing the youngest to the oldest age groups. This suggests that the oldest-old may face the greatest barriers to treatment access.

Good versus Poor Prognosis Cancers

Not all cancers showed the same pattern. Treatment differences—particularly the omission of therapy—were often smaller (typically less than 10%) for good-prognosis cancer types such as breast cancer. For example, one breast cancer study found relatively small differences in treatment rates between younger and older patients.

However, an exception was noted in cervical cancer, where 62% of younger patients underwent surgery compared to only 36% of older patients. For poor-prognosis cancers like lung and pancreatic cancer, differences in treatment rates across age groups were typically much larger.

Survival Outcomes

Across the board, older patients had poorer survival compared to middle-aged patients, regardless of whether the studies measured overall survival (how long patients lived regardless of cause of death) or cancer-specific survival (how long patients lived before dying specifically from their cancer). Survival differences were again most pronounced among patients over age 80.

Key Findings: Outcomes for Patients Selected for Treatment

The picture changes dramatically when the focus shifts to patients who actually received treatment. Among these selected patients, outcomes were often comparable between older and younger patients—a finding with profound clinical implications.

Surgical Patients

Among patients who underwent surgery, older patients were consistently less likely to receive neoadjuvant therapy (treatment given before surgery to shrink tumors) or adjuvant therapy (treatment given after surgery to prevent recurrence), regardless of cancer type. This trend appeared across gastric, esophageal, colon, rectal, pancreatic, ovarian, and other cancers.

However, for those who did undergo surgery, postoperative complication rates were frequently not significantly different between age groups. This was particularly true in pancreatic cancer studies, where complication rates were comparable across age groups. For colon and colorectal cancer, the results were mixed: some studies found significant differences in postoperative complications between age groups, while others found similar rates. The researchers noted that these differences may be explained by differences in which patients were selected for surgery in the first place.

One large colorectal cancer study highlighted the age-divide at 80. Complication rates were 13% versus 21% for colon cancer and 11% versus 23% for rectal cancer when comparing younger to older patients. Thirty-day mortality (death within 30 days of surgery) was 0.9 versus 3.3 for colon cancer and 0.4 versus 3.1 for rectal cancer, respectively.

Patients Receiving Systemic Treatment

Older patients receiving chemotherapy were less likely to complete their full treatment course, with lower completion rates reported in several studies. However, when older patients did receive the treatment, complications, adverse event rates, and survival were usually comparable to younger patients.

This was particularly notable for immunotherapy and chemotherapy. Studies on patients receiving immunotherapy found that the number of cycles or median doses received was similar between younger and older patients. Overall survival and progression-free survival (time before the cancer worsens) were comparable across age groups in most studies examining these therapies.

Among patients with poor-prognosis cancers like pancreatic cancer, adverse events after surgery were generally not significantly different between age groups. This held true across multiple studies and suggests that older patients can tolerate aggressive treatment when appropriately selected.

Clinical Implications: What This Means for Patients

The findings from this review carry several important messages. First, the consistent pattern of older patients receiving less treatment—including more frequent complete omission of therapy—raises the question of whether some of these decisions represent undertreatment rather than appropriately tailored care.

The researchers acknowledge that many valid reasons may explain why older patients do not receive treatment. These include:

• Poorer overall health status and frailty
• An unfavorable risk–benefit balance for some treatments
• Limited remaining life expectancy due to other conditions
• Patient preferences to avoid invasive treatments or side effects
• The presence of multiple chronic conditions (multimorbidity)

However, the review also highlights a concerning gap in scientific evidence. There is a lack of robust data on treatment effectiveness specifically in multimorbid and oldest patients. Without this evidence, treatment decisions are often made based on assumptions rather than data—potentially leading some older patients to be denied treatments that would benefit them.

Perhaps the most significant finding for patients is this: when older adults are selected for treatment, they experience comparable complications, adverse events, and survival rates to younger patients. This runs counter to the assumption that age itself makes treatment too risky or ineffective. The key appears to be careful patient selection based on individual health status rather than chronological age.

Study Limitations

The researchers noted several limitations of their review. Most of the included studies were conducted in Europe or the United States, with less representation from other regions of the world, which may limit the generalizability of findings to other healthcare systems and populations.

The majority of studies were also single-center reports, and many had relatively small sample sizes. The studies varied widely in their age cut-offs, cancer types, treatment settings, and outcome measures, making direct comparisons between studies difficult. Additionally, the review focused on papers published in English, which may exclude relevant research published in other languages.

Critically, because this was a review of observational studies (rather than randomized controlled trials), it cannot prove that age directly causes the treatment differences observed. Other unmeasured factors—such as frailty, cognitive status, social support, or life expectancy—could explain some of the differences attributed to age. Selection bias is also a significant concern: the fact that older patients who were selected for treatment did well may partly reflect that clinicians chose only the healthiest older patients for treatment—a phenomenon known as "selection of the fittest."

Recommendations for Patients and Families

Based on this research, older adults facing a cancer diagnosis and their families should consider the following:

1. Don't let age alone be the deciding factor. The evidence strongly suggests that many older patients can tolerate cancer treatment and achieve outcomes comparable to younger patients. Ask your care team to assess your overall health, frailty level, and functional status—not just your age.
2. Seek a comprehensive geriatric assessment. This type of evaluation goes beyond standard oncology assessment to look at your physical function, nutrition, cognitive health, medications, and social support. It can help your doctors predict whether you are likely to tolerate treatment well.
3. Ask about all treatment options. Older patients are less likely to be offered surgery, chemotherapy, radiation, or immunotherapy. If you are not offered a treatment, ask why—and whether your individual health status supports or rules it out.
4. Discuss the possibility of side effects with realistic expectations. While older patients selected for treatment had comparable complication rates to younger patients in the reviewed studies, treatment completion rates were lower. Working closely with your care team to manage side effects early may improve your chances of completing treatment.
5. Be aware of the gap at age 80. Differences in treatment rates and outcomes were most pronounced in patients over 80 years. If you or your loved one is in this age group, be especially proactive about ensuring that treatment decisions are based on individual health status and preferences, not assumptions about your age.
6. Make your wishes known. Patient preference is a valid and important reason to choose or decline treatment. Be clear with your care team about your priorities—whether that means prolonging life at all costs, preserving quality of life, or something in between.
7. Ask whether your cancer center routinely includes older adults in treatment decisions. Research participation matters. If you are asked to join a clinical trial, know that your participation helps build the evidence needed to improve cancer care for future generations of older adults.

The authors also emphasized an urgent research need: more studies on treatment in older cancer patients, particularly the frailest and the oldest, to provide the data needed to tailor treatments appropriately. As the population continues to age, filling this evidence gap becomes ever more critical.

In summary, while the review confirms that older adults receive less cancer treatment and fare worse in terms of survival, it also offers an important message of hope: older patients who are selected for treatment and choose to proceed can do remarkably well. The challenge—for both clinicians and patients—is ensuring that these selections are based on evidence and individual health status rather than age alone.

Frequently Asked Questions

My parent is over 80 and was just diagnosed with cancer. Are they too old for treatment?

No, age alone should not decide. The research found the largest treatment differences and poorer survival in patients over 80. However, when older patients are carefully selected for treatment, complication rates and survival are often comparable to younger patients. Ask your care team to assess your parent's overall health, frailty, and functional status, not just their age.

Should older adults receive the same cancer treatment as younger patients?

The research shows older patients are less likely to receive any cancer treatment, including surgery, chemotherapy, or radiation. Yet among those who do receive treatment, outcomes are often comparable to younger patients. The key is careful patient selection based on individual health status, frailty, and personal preferences, not chronological age alone. Treatment decisions should be individualized.

What is a comprehensive geriatric assessment and why does it matter?

It is an evaluation that goes beyond standard oncology assessment to look at physical function, nutrition, cognitive health, medications, and social support. The article recommends older adults facing cancer ask for one because it helps doctors predict whether they are likely to tolerate treatment well. This assessment supports decisions based on health status rather than age alone.

How much less likely are older patients to get cancer treatment?

Differences were consistent across studies. For example, in one pancreatic cancer study, 33% of younger patients received no treatment compared to 67% of patients over 60. For lung cancer in a German study, 4.4% of younger patients received no treatment versus 20.2% of those over 65, and 54.7% of those over 80.

Do older patients have more side effects from cancer treatment?

In the reviewed studies, when older patients were selected for treatment, complication rates and adverse events were frequently comparable to younger patients, particularly for immunotherapy and chemotherapy. However, older patients were less likely to complete their full treatment course. Working closely with your care team to manage side effects early may improve the chance of completing treatment.

Why are survival outcomes worse for older patients?

The review found that older patients had poorer overall and cancer-specific survival compared to middle-aged patients, with the largest differences in those over 80. However, the authors note this is an observational review, so it cannot prove that age directly causes worse outcomes. Factors like frailty, other illnesses, or treatment differences may explain some of the survival gaps.

What should I ask my oncology team about treatment options for my older parent?

Ask for a comprehensive geriatric assessment. Ask about all treatment options, and if a treatment is not offered, ask why and whether your parent's individual health supports or rules it out. Discuss realistic expectations about side effects and completion rates. Make your parent's wishes known—whether prioritizing quality of life or prolonging life—and ask how their age is influencing the recommendation.

Can a second opinion change the cancer treatment plan for an older adult?

Older adults are less likely to be offered cancer treatment, and treatment gaps widen after age 80. Yet among patients who receive treatment, complication rates and survival are often comparable to younger patients. A second opinion can help ensure that decisions rest on individual health status, frailty, and preferences—not on age alone. Ask about a comprehensive geriatric assessment and whether all treatment options have been considered. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Epidemiology of cancer in older adults: a systematic review of age-related differences in solid malignancies treatment.

Authors: Bastiaannet E, Pilleron S.

Journal: Current Oncology Reports (2025) 27:290–311

Publication date: Published online February 15, 2025 (accepted January 9, 2025)

DOI: https://doi.org/10.1007/s11912-025-01638-6

Review registration: PROSPERO CRD42023450654

This patient-friendly article is based on peer-reviewed research. The original systematic review was published under open access terms (© The Author(s) 2025).